Focused On-demand Library for Kinesin-like protein KIF3B

Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Reaxense helps in synthesizing and delivering these compounds.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We employ our advanced, specialised process to create targeted libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

PARTNER
Receptor.AI
 
UPACC
O15066

UPID:
KIF3B_HUMAN

ALTERNATIVE NAMES:
HH0048; Microtubule plus end-directed kinesin motor 3B

ALTERNATIVE UPACC:
O15066; B2RMP4; B4DSR5; E1P5M5

BACKGROUND:
The Kinesin-like protein KIF3B, with alternative names HH0048 and Microtubule plus end-directed kinesin motor 3B, is essential for intracellular cargo transport. It binds and moves along microtubules, facilitating ATP hydrolysis-driven force generation. KIF3B's functions extend to cilia formation, opsin trafficking in rod photoreceptors, and the transport of NMDA receptor subunit GRIN2A-containing vesicles, highlighting its critical role in cellular and neurological processes.

THERAPEUTIC SIGNIFICANCE:
Kinesin-like protein KIF3B's association with Retinitis pigmentosa 89, a condition marked by retinal pigment deposits and photoreceptor cell loss, underscores its potential as a therapeutic target. Exploring Kinesin-like protein KIF3B's functions could lead to innovative treatments for retinal dystrophies and other ciliopathy-related conditions.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.


Page 8643 of 8789